Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308 · see citing works

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Isho, B., Abe, K. T., Zuo, M., Jamal, A. J., Rathod, B., Wang, J. H., Li, Z., Chao, G., Rojas, O. L., Bang, Y. M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe5511 · Cited by 822 · see citing works

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Wang, Z., Muecksch, F., Schaefer-Babajew, D., Finkin, S., Viant, C., Gaebler, C., Hoffmann, H. H., Barnes, C. O., Cipolla, M., Ramos, V., et al. (2021) · Nature · doi:10.1038/s41586-021-03696-9 · Cited by 721 · see citing works

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite

Cerutti, G., Guo, Y., Zhou, T., Gorman, J., Lee, M., Rapp, M., Reddem, E. R., Yu, J., Bahna, F., Bimela, J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.005 · Cited by 519 · see citing works

Antibody response to SARS-CoV-2 infection in humans: A systematic review

Post, N., Eddy, D., Huntley, C., van Schalkwyk, M. C., Shrotri, M., Leeman, D., Rigby, S., Williams, S. V., Bermingham, W. H., Kellam, P., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0244126 · Cited by 367 · see citing works

Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection

Reynolds, C. J., Swadling, L., Gibbons, J. M., Pade, C., Jensen, M. P., Diniz, M. O., Schmidt, N. M., Butler, D. K., Amin, O. E., Bailey, S. N. L., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abf3698 · Cited by 191 · see citing works

A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases

He, S., Gui, J., Xiong, K., Chen, M., Gao, H., & Fu, Y. S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01307-x · Cited by 188 · see citing works

Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions

Bunders, M. J., & Altfeld, M. A. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.003 · Cited by 163 · see citing works

Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins

Wang, Z., Muecksch, F., Cho, A., Gaebler, C., Hoffmann, H.-H., Ramos, V., Zong, S., Cipolla, M., Johnson, B., Schmidt, F., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.003 · Cited by 142 · see citing works

SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants

Tea, F., Stella, A. O., Aggarwal, A., Darley, D. R., Pilli, D., Vitale, D., Merheb, V., Lee, F. X. Z., Cunningham, P., Walker, G. J., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003656 · Cited by 134 · see citing works

Disease diagnostics using machine learning of B cell and T cell receptor sequences

Zaslavsky, M., Craig, E., Michuda, J., Sehgal, N., Ram-Mohan, N., Lee, J.-Y., Nguyen, K. D., Hoh, R. A., Pham, T. D., Röltgen, K., et al. (2025) · Science · doi:10.1126/science.adp2407 · Cited by 123 · see citing works

Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects

Jennewein, M. F., MacCamy, A. J., Akins, N. R., Feng, J., Homad, L. J., Hurlburt, N., Seydoux, E., Wan, Y.-H., Stuart, A., Edara, V., et al. (2021) · bioRxiv · doi:10.1016/j.celrep.2021.109353 · Cited by 128 · see citing works

Rapid isolation and immune profiling of SARS-CoV-2 specific memory B cell in convalescent COVID-19 patients via LIBRA-seq

He, B., Liu, S., Wang, Y., Xu, M., Cai, W., Liu, J., Bai, W., Ye, S., Ma, Y., Hu, H., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00610-7 · Cited by 83 · see citing works

SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies

Reincke, S. M., Yuan, M., Kornau, H., Corman, V. M., van Hoof, S., Sánchez-Sendín, E., Ramberger, M., Yu, W., Hua, Y., Tien, H. J., et al. (2022) · Science · doi:10.1126/science.abm5835 · Cited by 73 · see citing works

Longitudinal antibody repertoire in “mild” versus “severe” COVID-19 patients reveals immune markers associated with disease severity and resolution

Ravichandran, S., Lee, Y., Grubbs, G., Coyle, E. M., Klenow, L., Akasaka, O., Koga, M., Adachi, E., Saito, M., Nakachi, I., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf2467 · Cited by 73 · see citing works

Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2

Planchais, C., Fernández, I., Bruel, T., de Melo, G. D., Prot, M., Beretta, M., Guardado‐Calvo, P., Dufloo, J., Molinos-Albert, L. M., Backović, M., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220638 · Cited by 69 · see citing works

Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects

Zheng, J., Deng, Y., Zhao, Z., Mao, B., Lu, M.-J., Lin, Y., & Huang, A.-L. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00774-w · Cited by 56 · see citing works

SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness

Jeewandara, C., Jayathilaka, D., Gomes, L., Wijewickrama, A., Narangoda, E., Idampitiya, D., Guruge, D., Wijayamuni, R., Manilgama, S. R., Ogg, G. S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81629-2 · Cited by 55 · see citing works

Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level

Akerman, A., Milogiannakis, V., Jean, T., Esneau, C., Silva, M. R., Ison, T., Fichter, C., Lopez, J. A., Chandra, D., Naing, Z., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104545 · Cited by 57 · see citing works

Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors

Mor, M., Werbner, M., Alter, J., Safra, M., Chomsky, E., Lee, J. C., Hada-Neeman, S., Polonsky, K., Nowell, C., Clark, A., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009165 · Cited by 47 · see citing works

Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues

Yang, F., Nielsen, S. C. A., Hoh, R., Röltgen, K., Wirz, O., Haraguchi, E., Jean, G. H., Lee, J.-Y., Pham, T., Jackson, K., et al. (2020) · Science · doi:10.1126/science.abf6648 · Cited by 58 · see citing works

Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies

Krähling, V., Halwe, S., Rohde, C., Becker, D., Berghöfer, S., Dahlke, C., Eickmann, M., Ercanoglu, M. S., Gieselmann, L., Herwig, A., et al. (2021) · Journal of Immunological Methods · doi:10.1016/j.jim.2021.112958 · Cited by 48 · see citing works

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies

Muecksch, F., Weisblum, Y., Barnes, C. O., Schmidt, F., Schaefer-Babajew, D., Lorenzi, J. C. C., Flyak, A. I., DeLaitsch, A. T., Huey-Tubman, K. E., Hou, S., et al. (2021) · doi:10.1101/2021.03.07.434227 · Cited by 39 · see citing works

Pathogenic lipid‐binding antiphospholipid antibodies are associated with severity of COVID‐19

Hollerbach, A., Müller‐Calleja, N., Pedrosa, D., Canisius, A., Sprinzl, M. F., Falter, T., Rossmann, H., Bodenstein, M., Werner, C. D., Sagoschen, I., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15455 · Cited by 38 · see citing works

Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitroPreprint

Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Viant, C., Gaebler, C., Cipolla, M., Hoffmann, H.-H., Oliveira, T. Y., Oren, D. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.09.288555 · Cited by 35 · see citing works

Next-Generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody Repertoire

Melani, R. D., Soye, B. J. D., Kafader, J. O., Forte, E., Hollas, M. A. R., Blagojevic, V., Negrão, F., McGee, J. P., Drown, B., Lloyd-Jones, C., et al. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00882 · Cited by 32 · see citing works

Recombinant neutralizing secretory IgA antibodies for preventing mucosal acquisition and transmission of SARS-CoV-2

Göritzer, K., Groppelli, E., Grünwald‐Gruber, C., Figl, R., Ni, F., Hu, H., Li, Y., Liu, Y., Hu, Q., Puligedda, R. D., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.025 · Cited by 31 · see citing works

Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries

Yuan, T. Z., Garg, P., Wang, L., Willis, J. R., Kwan, E., Hernandez, A. G. L., Tuscano, E., Sever, E. N., Keane, E., Soto, C. S., et al. (2021) · mAbs · doi:10.1080/19420862.2021.2002236 · Cited by 25 · see citing works

Pathogenic autoantibodies to IFN-γ act through the impedance of receptor assembly and Fc-mediated response

Shih, H.-P., Ding, J.-Y., Bellón, J. S., Lo, Y.-F., Chung, P.-H., Ting, H.-T., Peng, J.-J., Wu, T.-Y., Lin, C., Lo, C.-C., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20212126 · Cited by 27 · see citing works

Phenotypic determinism and stochasticity in antibody repertoires of clonally expanded plasma cells

Neumeier, D., Yermanos, A., Agrafiotis, A., Csepregi, L., Chowdhury, T., Ehling, R. A., Kuhn, R., Cotet, T.-S., Roberto, R. B.-D., Tacchio, M. D., et al. (2021) · bioRxiv · doi:10.1073/pnas.2113766119 · Cited by 23 · see citing works

Clinical evaluation of commercial automated SARS-CoV-2 immunoassays

Kittel, M., Muth, M.-C., Zahn, I., Roth, H. J., Thiaucourt, M., Gerhards, C., Haselmann, V., Neumaier, M., & Findeisen, P. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.12.003 · Cited by 20 · see citing works

Convalescent plasma treatment of critically ill intensive care COVID ‐19 patients

Lindemann, M., Lenz, V., Knop, D., Klump, H., Alt, M., Aufderhorst, U. W., Schipper, L., Schwarzkopf, S., Meller, L., Steckel, N. K., et al. (2021) · Transfusion · doi:10.1111/trf.16392 · Cited by 18 · see citing works

Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern

Kovačech, B., Fialova, L., Filipcik, P., Škrabana, R., Zilkova, M., Paulenka-Ivanovova, N., Kováč, A., Palova, D., Rolkova, G., Tomková, K., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103818 · Cited by 16 · see citing works

SARS‐CoV‐2 sculpts the immune system to induce sustained virus‐specific naïve‐like and memory B‐cell responses

de Campos‐Mata, L., Vaquero, S. T., Tachó‐Piñot, R., Piñero, J., Grasset, E. K., Arrieta‐Aldea, I., Melero, N. R., Carolis, C., Horcajada, J. P., Cerutti, A., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1339 · Cited by 17 · see citing works

Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike ProteinsPreprint

Wang, Z.-J., Muecksch, F., Cho, A., Gaebler, C., Hoffmann, H., Ramos, V. A., Zong, S., Cipolla, M., Johnson, B., Schmidt, F., et al. (2022) · bioRxiv · doi:10.1101/2022.02.01.478695 · Cited by 20 · see citing works

Acute Surge of Atypical Memory and Plasma B-Cell Subsets Driven by an Extrafollicular Response in Severe COVID-19

Lee, T., Kim, Y., Kim, H. J., Ha, N., Lee, S., Chin, B., & Cho, N. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.909218 · Cited by 15 · see citing works

The Transient IFN Response and the Delay of Adaptive Immunity Feature the Severity of COVID-19

Xu, G., Qi, F., Wang, H., Liu, Y., Wang, X., Zou, R., Yuan, J., Liao, X., Liu, Y., Zhang, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.816745 · Cited by 15 · see citing works

Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers

Zaffina, S., Alteri, C., Ruggiero, A., Cotugno, N., Vinci, M. R., Camisa, V., Santoro, A. P., Brugaletta, R., Deriu, G. P., Mortari, E. P., et al. (2021) · Journal of Virus Eradication · doi:10.1016/j.jve.2021.100046 · Cited by 13 · see citing works

Comparison of two assays to detect IgG antibodies to the receptor binding domain of SARS‑CoV‑2 as a surrogate marker for assessing neutralizing antibodies in COVID-19 patients

Kamaladasa, A., Gunasekara, B., Jeewandara, C., Jayathilaka, D., Wijewickrama, A., Guruge, D., Wijayamuni, R., Tan, T. K., Ogg, G. S., Townsend, A., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.06.031 · Cited by 13 · see citing works

COVID-19 – pathogenesis and immunological findings across the clinical manifestation spectrum

Carsetti, R., Quinti, I., & Locatelli, F. (2021) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000775 · Cited by 12 · see citing works

Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual

Guerra, D., Beaumont, T., Radić, L., Kerster, G., van der Straten, K., Yuan, M., Torres, J. L., Lee, W.-H., Liu, H., Poniman, M., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108009 · Cited by 12 · see citing works

Potent NTD-Targeting Neutralizing Antibodies against SARS-CoV-2 Selected from a Synthetic Immune System

Li, W., Wang, F., Li, Y., Yan, L., Liu, L., Zhu, W., Ma, P., Shi, X., & Yang, G. (2023) · Vaccines · doi:10.3390/vaccines11040771 · Cited by 11 · see citing works

A key F27I substitution within HCDR1 facilitates the rapid maturation of P2C-1F11-like neutralizing antibodies in a SARS-CoV-2-infected donor

Wang, M., Fan, Q., Zhou, B., Ye, H., Shen, S., Yu, J., Cheng, L., Ge, X., Ju, B., & Zhang, Z. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111335 · Cited by 9 · see citing works

Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection

Sulbarán, G., Maisonnasse, P., Amen, A., Effantin, G., Guilligay, D., Dereuddre‐Bosquet, N., Burger, J. A., Poniman, M., Grobben, M., Buisson, M., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100528 · Cited by 10 · see citing works

Computational approach for binding prediction of SARS-CoV-2 with neutralizing antibodies

Beshnova, D., Fang, Y., Du, M., Sun, Y., Du, F.-H., Ye, J., Chen, Z.-J. J., & Li, B. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.04.038 · Cited by 9 · see citing works

Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern

Cohen‐Dvashi, H., Weinstein, J. J., Katz, M., Eilon-Ashkenazy, M., Mor, Y., Shimon, A., Achdout, H., Tamir, H., Israely, T., Strobelt, R., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105193 · Cited by 9 · see citing works

Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ SubjectsPreprint

Jennewein, M. F., MacCamy, A. J., Akins, N. R., Feng, J., Homad, L. J., Hurlburt, N. K., Seydoux, E., Wan, Y.-H., Stuart, A. B., Edara, V. V., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.23.436684 · Cited by 9 · see citing works

Full-Length Immune Repertoire Reconstruction and Profiling at the Transcriptome Level Using Long-Read Sequencing

Luo, X., Zhang, L., Li, Y., Li, C., Sun, G., Zhang, C., Fu, Y., Lv, H., Liu, M., Cui, H., et al. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae138 · Cited by 7 · see citing works

Structural basis for hepatitis E virus neutralization by potent human antibodies

Molinos-Albert, L. M., Baquero, E., Planchais, C., Doceul, V., Costa, H. E., Mottez, E., Mallet, V. O., Pol, S., Albert, M. L., Pavio, N., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu8811 · Cited by 7 · see citing works

SARS-CoV-2 S Glycoprotein Stabilization Strategies

Pedenko, B., Sulbarán, G., Guilligay, D., Effantin, G., & Weissenhorn, W. (2023) · Viruses · doi:10.3390/v15020558 · Cited by 7 · see citing works

In silico analysis suggests less effective MHC-II presentation of SARS-CoV-2 RBM peptides: Implication for neutralizing antibody responses

Castro, A., Ozturk, K., Zanetti, M., & Carter, H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246731 · Cited by 6 · see citing works

Anti-Spike Antibody Response to Natural Infection with SARS-CoV-2 and Its Activity against Emerging Variants

Chen, C., Huang, K.-Y. A., Shih, S., Lin, Y., Cheng, C., Huang, Y., Lin, T., & Cheng, S. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00743-22 · Cited by 7 · see citing works

Elevated SARS-CoV-2 Antibodies Distinguish Severe Disease in Early COVID-19 InfectionPreprint

Haddad, N. S., Nguyen, D. C., Kuruvilla, M. E., Morrison-Porter, A., Anam, F. A., Cashman, K. S., Ramonell, R. P., Kyu, S. Y., Saini, A. S., Cabrera-Mora, M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.04.410589 · Cited by 7 · see citing works

The characteristics of BCR‐CDR3 repertoire in COVID‐19 patients and SARS‐CoV‐2 vaccinated volunteers

Xiao, J., Luo, Y., Li, Y., & Yao, X.-S. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29488 · Cited by 5 · see citing works

SARS-CoV-2 receptor binding domain-specific antibodies activate platelets with features resembling the pathogenic antibodies in heparin-induced thrombocytopeniaPreprint

Zhu, W., Zheng, Y., Yu, M., Wei, J., Zhang, Y., Topchyan, P., Nguyen, C. P., Janecke, R., Kreuziger, L. B., White, G. C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-462080/v1 · Cited by 6 · see citing works

Quantity of IgG response to SARS-CoV-2 spike glycoprotein predicts pulmonary recovery from COVID-19

Nairz, M., Sahanic, S., Pizzini, A., Boehm, A., Tymoszuk, P., Mitterstiller, A., von Raffay, L., Grubwieser, P., Bellmann‐Weiler, R., Koppelstätter, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07489-6 · Cited by 5 · see citing works

Naive and Memory B Cell BCR Repertoires in Individuals Immunized with an Inactivated SARS-CoV-2 Vaccine

França, R. K. A. D. O., Barros, P. H. A., Silva, J. M., Fontinele, H. G. C., Maranhão, A. Q., & Brígido, M. M. (2025) · Vaccines · doi:10.3390/vaccines13040393 · Cited by 4 · see citing works

Properties of RBD specific IgG from COVID-19 patients and Sputnik V vaccinated individuals

Generalova, L., Grigoriev, I. V., Vasina, D. V., Ap, T., Сергеевна, К. И., Колобухина, Л. В., Burgasova, O., & Gushchin, V. А. (2022) · Bulletin of Russian State Medical University · doi:10.24075/brsmu.2022.005 · Cited by 3 · see citing works

Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method

Dou, Y., Xu, K., Deng, Y., Jia, Z., Lan, J., Xu, X., Zhang, G., Cao, T.-S., Liu, P., Wang, X., et al. (2023) · Antibody Therapeutics · doi:10.1093/abt/tbad002 · Cited by 3 · see citing works

The multilevel extensive diversity across the cynomolgus macaque captured by ultra-deep adaptive immune receptor repertoire sequencing

Zhu, Y., Tang, H., Xie, W., Chen, S., Zeng, H., Lan, C., Guan, J., Ma, C., Yang, X., Wang, Q., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj5640 · Cited by 3 · see citing works

Differential Kinetics of T Cell and Antibody Responses Delineate Dominant T Cell Epitopes in Long-Term Immunity after COVID-19Preprint

Bilich, T., Nelde, A., Heitmann, J. S., Maringer, Y., Roerden, M., Bauer, J., Rieth, J., Wacker, M., Peter, A., Hörber, S., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3713528 · Cited by 3 · see citing works

Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants

Oladunni, F. S., Park, J.-G., Chiem, K., Ye, C.-J., Pipenbrink, M., Walter, M., Kobie, J., & Martínez-Sobrido, L. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114084 · Cited by 2 · see citing works

Somatic Evolution of a Germline Antibody Expands its Breadth to Neutralize Early SARS‐CoV‐2 Omicron Variants

Lv, H., Feng, Z., Teo, Q. W., Chen, C., Gopal, A. B., Choi, D., Tan, T. J. C., Tang, Y. S., Siu, L. Y.-L., Nourmohammad, A., et al. (2026) · Advanced Science · doi:10.1002/advs.76522 · Cited by 2 · see citing works

MHC-II constrains the natural neutralizing antibody response to the SARS-CoV-2 spike RBM in humansPreprint

Castro, A., Ozturk, K., Zanetti, M., & Carter, H. (2020) · bioRxiv · doi:10.1101/2020.12.26.424449 · Cited by 1 · see citing works

Arrayed multicycle drug screens identify broadly acting chemical inhibitors for repurposing against SARS-CoV-2Preprint

Murer, L., Volle, R., Andriasyan, V., Meili, N., Yang, L., Sequeira, D. P., Gómez-González, A., Petkidis, A., Olszewski, D., Bauer, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.30.437771 · Cited by 1 · see citing works

Second-Generation Antibodies Neutralize Emerging SARS-CoV-2 Variants of ConcernPreprint

Kovačech, B., Fialova, L., Filipcik, P., Škrabana, R., Zilkova, M., Paulenka-Ivanovova, N., Kováč, A., Palova, D., Rolkova, G. P., Tomková, K., et al. (2021) · bioRxiv · doi:10.1101/2021.06.09.447527

Public antibody clonotypes and deep learning identify SARS-CoV-2 and HIV broadly neutralizing antibodies in immune repertoires

Zhou, L., 余志立, Lin, S., Jiang, Y., Gao, J., Ma, Y., Jiang, W., Liang, S., Chen, Y., Zhang, Y., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117582

SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms

Clark, S., Clark, L., Pan, J., Coscia, A., McKay, L. G. A., Shankar, S., Johnson, R. I., Brusic, V., Choudhary, M., Regan, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.027 · Cited by 176 · see citing works

Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody librariesPreprint

Lou, Y., Zhao, W., Wei, H., Chu, M. G., Chao, R., Yao, H., Su, J., Li, Y., Li, X., Cao, Y., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.06.137513 · Cited by 9 · see citing works

Correlation between Commercial Anti-RBD IgG Titer and Neutralization Titer against SARS-CoV-2 Beta Variant

Poon, R. W., Lu, L., Fong, C. H.-Y., Ip, T.-C., Chen, L., Zhang, R., Yip, C. C., Cheng, V. C., Chan, K., Yuen, K., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11122216 · Cited by 5 · see citing works

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

Seydoux, E., Homad, L. J., MacCamy, A. J., Parks, K. R., Hurlburt, N. K., Jennewein, M. F., Akins, N. R., Stuart, A. B., Wan, Y.-H., Feng, J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.001 · Cited by 364 · see citing works

Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection

Wan, J., Xing, S., Ding, L., Wang, Y., Gu, C., Wu, Y., Rong, B., Li, C., Wang, S., Chen, K., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107918 · Cited by 152 · see citing works